Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2017 | 2016 | 2013 | 2012
Number of items: 7.

2017

Brueckl, W. M., Wirtz, R. M., Bertsch, T., Ficker, J. H. and Jung, A. (2017). Liquid Biopsy: Detection of Molecular Markers for Treatment Decisions in Lung Cancer. Pneumologie, 71 (3). S. 151 - 164. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

Wirtz, R. M., Scheffen, I., Marme, F., Laible, M., Sclombs, K., Schumacher, C., Schneeweiss, A., Eidt, S. and Sinn, H-P (2017). Predictive value of ultra-high ESR1 mRNA expression in early breast cancer. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

2016

Wirtz, R. M., Fritz, V., Stoehr, R. and Hartmann, A. (2016). Molecular classification of bladder cancer. Possible similarities to breast cancer. Pathologe, 37 (1). S. 52 - 61. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963

2013

Wirtz, R. M., Aigner, J., Marme, F., Eidt, S., Altevogt, P., Sinn, P. and Schneeweiss, A. (2013). High tumor CD68 mRNA content (intratumoral macrophages) predicts response to neoadjuvant chemotherapy. Cancer Res., 73. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Wirtz, R. M., Leinonen, M., Bono, P., Isola, J., Kellokumpu-Lehtinen, P-L, Kataja, V., Turpeenniemi-Hujanen, T., Jyrkkio, S., Eidt, S., Schmidt, M. and Joensuu, H. (2013). Low tumor CD68 mRNA content (intratumoral macrophages) is predictive for benefit from adjuvant trastuzumab in HER2-positive breast cancer: An analysis of the FinHER trial. Cancer Res., 73. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

2012

Marme, F., Schneeweiss, A., Aigner, J., Eidt, S., Altevogt, P., Sinn, P. and Wirtz, R. M. (2012). Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer. Cancer Res., 72. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Wirtz, R. M., Leinonen, M., Bono, P., Isola, J., Kellokumpu-Lehtinen, P-L, Kataja, V., Turpeenniemi-Hujanen, T., Jyrkkio, S., Eidt, S., Schmidt, M. and Joensuu, H. (2012). CXCL13 mRNA predicts Docetaxel benefit in Triple Negative tumors. Cancer Res., 72. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

This list was generated on Tue Apr 23 09:46:57 2024 CEST.